Annexon, Inc. (ANNX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Douglas Love
Employees:
70
180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO, CA 94080
(650)-822-5500

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain-baré syndrome. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Data derived from most recent annual or quarterly report
Market Cap 182.424 Million Shares Outstanding47.63 Million Avg 30-day Volume 572.292 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.96
Price to Revenue0.0 Debt to Equity0.0 EBITDA-127.319 Million
Price to Book Value1.8984 Operating Margin0.0 Enterprise Value197.539 Million
Current Ratio11.391 EPS Growth0.181 Quick Ratio11.162
1 Yr BETA 0.9494 52-week High/Low 7.65 / 2.06 Profit Margin0.0
Operating Cash Flow Growth-99.8794 Altman Z-Score2.788 Free Cash Flow to Firm -87.621 Million
Earnings Report2023-05-08
View SEC Filings from ANNX instead.

View recent insider trading info

Annexon, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ANNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANNX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-21 by LOVE DOUGLAS
  • 4: filed on 2023-02-21 by OVERDORF MICHAEL
  • 4: filed on 2023-02-21 by LEW JENNIFER
  • 4: filed on 2023-02-17 by LOVE DOUGLAS
  • 4: filed on 2023-02-15 by OVERDORF MICHAEL
  • 4: filed on 2023-02-15 by LEW JENNIFER
  • 4: filed on 2023-02-14 by SATTER MUNEER A
  • 4: filed on 2023-01-18 by ARTIS DEAN RICHARD
  • 3: filed on 2023-01-12 by ARTIS DEAN RICHARD
  • 4: filed on 2022-07-13 by OVERDORF MICHAEL

    • Events (8k)

  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    2.6 Million total shares from 1 transactions

    Open Market Sells (S)

    10.1 Thousand total shares from 5 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LEW JENNIFER EVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 48,517 2023-02-16 3

    LOVE DOUGLAS PRESIDENT & CEO

    • Officer
    • Director
    		 0 2023-02-16 6

    OVERDORF MICHAEL EVP & CHIEF BUSINESS OFFICER

    • Officer
    		 46,780 2023-02-16 3

    SATTER MUNEER A

    • Director
    • 10% Owner
    		 7,056,024 2023-02-10 3

    ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 210,000 2023-01-15 2

    MATTHEAKIS LARRY EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 54,688 2022-07-11 2

    WIGGANS THOMAS G

    • Director
    		 24,000 2022-06-09 1

    WADDILL WILLIAM D.

    • Director
    		 24,000 2022-06-09 1

    CHOI JUNG

    • Director
    		 24,000 2022-06-09 1

    CARSON WILLIAM H.

    • Director
    		 24,000 2022-06-09 1

    COCKROFT BETTINA M.

    • Director
    		 24,000 2022-06-09 1

    KESWANI SANJAY EVP & CHIEF MEDICAL OFFICER

    • Officer
    		 112,500 2022-02-11 0

    YEDNOCK TED EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 78,554 2021-09-13 0

    SUN RICKY

    • Director
    		 10,000 2021-06-02 0

    FLYNN JAMES E

    DEERFIELD MGMT IV, L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD PRIVATE DESIGN FUND IV, L.P.

    DEERFIELD MGMT L.P.

    DEERFIELD PARTNERS, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2020-07-28 0

    CLARUS LIFESCIENCES III, L.P.

    CLARUS VENTURES III GP, L.P.

    BLACKSTONE CLARUS III L.L.C.

    BLACKSTONE HOLDINGS II L.P.

    BLACKSTONE HOLDINGS I/II GP L.L.C.

    BLACKSTONE GROUP INC

    BLACKSTONE GROUP MANAGEMENT L.L.C.

    SCHWARZMAN STEPHEN A

    • 10% Owner
    		 No longer subject to file 2020-07-28 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    		 No longer subject to file 2020-07-28 0

    BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC

    BAIN CAPITAL LIFE SCIENCES FUND, L.P.

    BCIP LIFE SCIENCES ASSOCIATES, LP

    KOPPEL ADAM

    BAIN CAPITAL LIFE SCIENCES PARTNERS, LP

    SCHWARTZ JEFFREY LAWRENCE

    • 10% Owner
    		 No longer subject to file 2020-07-28 0

    MAKOWER JOSHUA

    • 10% Owner
    		 0 2020-07-23 0

    YOUNG WILLIAM

    • Director
    		 0 2020-07-23 0

    SANDELL SCOTT D

    • 10% Owner
    		 0 2020-07-23 0

    BASKETT FOREST

    • 10% Owner
    		 0 2020-07-23 0

    GALLAGHER CAROL GILTNER

    • Director
    		 0 2020-07-23 0

    SONSINI PETER W.

    • 10% Owner
    		 0 2020-07-23 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    		 0 2020-07-23 0

    NEW ENTERPRISE ASSOCIATES 15, L.P.

    NEA PARTNERS 15, L.P.

    NEA 15 GP, LLC

    • 10% Owner
    		 0 2020-07-23 0

    MAKHZOUMI MOHAMAD

    • 10% Owner
    		 0 2020-07-23 0

    CUNNINGHAM EMMETT

    • Director
    		 0 2020-07-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    LOVE DOUGLAS - Director - Officer PRESIDENT & CEO

    		2023-02-21 17:28:32 -0500 2023-02-16 A 345,000 a 345,000 direct

    OVERDORF MICHAEL - Officer EVP & CHIEF BUSINESS OFFICER

    		2023-02-21 17:27:06 -0500 2023-02-16 A 18,975 a 46,780 direct -1.5483 -6.9217 0.0 1 -6.9217 6

    OVERDORF MICHAEL - Officer EVP & CHIEF BUSINESS OFFICER

    		2023-02-21 17:27:06 -0500 2023-02-16 A 77,050 a 77,050 direct

    LEW JENNIFER - Officer EVP & CHIEF FINANCIAL OFFICER

    		2023-02-21 17:26:07 -0500 2023-02-16 A 18,975 a 48,517 direct -1.5483 -6.9217 0.0 1 -6.9217 6

    LEW JENNIFER - Officer EVP & CHIEF FINANCIAL OFFICER

    		2023-02-21 17:26:07 -0500 2023-02-16 A 77,050 a 77,050 direct

    LOVE DOUGLAS - Director - Officer PRESIDENT & CEO

    		2023-02-17 17:12:31 -0500 2023-02-15 S 6,571 $5.87 d 197,646 direct -4.3554 -7.1429 0.0 1 -7.1429 6

    OVERDORF MICHAEL - Officer EVP & CHIEF BUSINESS OFFICER

    		2023-02-15 19:00:45 -0500 2023-02-14 S 144 $6.30 d 27,805 direct 0.1684 -9.2593 0.1684 2 -9.2593 6

    LEW JENNIFER - Officer EVP & CHIEF FINANCIAL OFFICER

    		2023-02-15 18:59:57 -0500 2023-02-14 S 166 $6.30 d 29,542 direct 0.1684 -9.2593 0.1684 2 -9.2593 6

    OVERDORF MICHAEL - Officer EVP & CHIEF BUSINESS OFFICER

    		2023-02-15 19:00:45 -0500 2023-02-13 S 1,501 $6.30 d 27,949 direct 0.1684 -9.2593 0.1684 2 -9.2593 6

    LEW JENNIFER - Officer EVP & CHIEF FINANCIAL OFFICER

    		2023-02-15 18:59:57 -0500 2023-02-13 S 1,742 $6.31 d 29,708 direct 0.1684 -9.2593 0.1684 2 -9.2593 6

    SATTER MUNEER A - Director - > 10% Owner see footnote

    		2023-02-14 16:31:56 -0500 2023-02-10 P 2,647,058 $6.80 a 7,056,024 indirect 0.678 -8.3898 0.8475 3 -8.3898 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ANNEXON INC ANNX 2023-03-24 22:15:03 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 21:45:03 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 21:15:03 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 20:45:03 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 20:15:04 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 19:45:03 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 19:15:04 UTC 3.9586 0.8614 350000
    ANNEXON INC ANNX 2023-03-24 18:45:04 UTC 3.968 0.852 350000
    ANNEXON INC ANNX 2023-03-24 18:15:03 UTC 3.968 0.852 350000
    ANNEXON INC ANNX 2023-03-24 17:45:03 UTC 3.968 0.852 350000
    ANNEXON INC ANNX 2023-03-24 17:15:03 UTC 3.968 0.852 350000
    ANNEXON INC ANNX 2023-03-24 16:45:03 UTC 3.968 0.852 350000
    ANNEXON INC ANNX 2023-03-24 16:15:03 UTC 3.968 0.852 200000
    ANNEXON INC ANNX 2023-03-24 15:45:03 UTC 3.968 0.852 200000
    ANNEXON INC ANNX 2023-03-24 15:15:03 UTC 3.968 0.852 300000
    ANNEXON INC ANNX 2023-03-24 14:45:03 UTC 3.968 0.852 300000
    ANNEXON INC ANNX 2023-03-24 14:15:03 UTC 3.968 0.852 150000
    ANNEXON INC ANNX 2023-03-24 13:45:03 UTC 4.0496 0.5204 150000
    ANNEXON INC ANNX 2023-03-24 13:15:04 UTC 4.0496 0.5204 150000
    ANNEXON INC ANNX 2023-03-24 12:45:03 UTC 4.0496 0.5204 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments